Company shares last traded at $0.55 which is marginally higher than $0.53, the 50 day moving average and which is slightly below the 200 day moving average of $0.58. The 50 day moving average was up $0.02 whereas the 200 day average was down by -6.173%. (NASDAQ:RXII) shares saw light trading volume with 442K shares changing hands by the end of trading on Tuesday. Overall, volume was down 25.84% under the stocks normal daily volume.
Investors are more bearish on the company lately at least if you consider the change in short interest. The company had a rise in short interest of 0.37% between September 29, 2017 and October 13, 2017. Short shares grew 6,906 over that period. The days to cover decreased to 3.0 and the short interest percentage is 0.28% as of October 13.
There has been some buying and selling insider activity on RXi Pharmaceuticals Corporation (NASDAQ:RXII) recently. President & CEO Geert Cauwenbergh disclosed the purchase of 10,000 shares of (RXII). The shares were purchased at an average price of $0.55. The President & CEO now owns $72,921 of the stock per the Form 4 SEC filing. Alexey Eliseev, Chief Business Officer sold $13,224 worth of shares at an average price of $0.57 on Fri the 1st. The Chief Business Officer now owns $642,454 of the stock as reported to the SEC.
Alexey Eliseev, Chief Business Officer disclosed the sale of 176,800 shares. The shares were sold on September 7th for a price of $0.54. Eliseev now owns $513,168 of the stock according to the SEC filing.
Additionally, here are a few investment firms who have increased or decreased their stake in (RXII). Citadel Advisors LLC cut its position by selling 42,852 shares a decrease of 47.1%. Citadel Advisors LLC currently owns 48,167 shares with a value of $28,000. The total value of its holdings increased 12.0%.
RXi Pharmaceuticals Corporation, launched on October 8, 2011, is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Business’s development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator. Its clinical development programs include RXI-109, an sd-rxRNA, for the treatment of dermal and ocular scarring, and Samcyprone for the treatment of such disorders as warts, alopecia areata, non-malignant skin tumors and cutaneous metastases of melanoma. In addition to these clinical programs, it has a pipeline of discovery and preclinical product candidates in its therapeutic areas, as well as in other areas of interest. Its pipeline is focused on approximately three areas, including dermatology, ophthalmology and cosmetic product development. Its RNAi therapies are designed to silence, or down-regulate, the expression of a specific gene that may be over-expressed in a disease condition and its immunotherapy agent treats diseases by inducing, enhancing or suppressing an immune response..